Zhaleh Jamali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhaleh Jamali has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Salimi
Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
1 shared publication- Fahimeh Mohseni
Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences https://dx.doi.org/154204 Shahroud Iran
1 shared publication Kasra Rahimi
Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
1 shared publication- Khatereh Isazadehfar
Department of Preventive and Community Medicine, Clinical Research Development Unit, Buali Hospital, Ardabil University of Medical Sciences, Ardabil, Iran
1 shared publication - Mohammad Niroumand Sarvandani
HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman 7616913555, Iran
1 shared publication - Raheleh Rafaiee
Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-26
Mitochondrial Dysfunction Across the Addiction Cycle: A Stage-Resolved Narrative Review
Addiction is a chronic, relapsing brain disorder defined by compulsive drug use, diminished self-control, and persistent vulnerability to relapse. Although addiction is conventionally framed in terms of synaptic and circuit-level adaptations within the mesolimbic dopamine system, prefrontal cortex, hippocampus, and amygdala, accumulating evidence indicates that these neuroadaptations are themselves substantially dependent on the bioenergetic integrity of the neurons that compose these circuits. Mitochondria, as the principal site of ATP synthesis, calcium buffering, and redox regulation, occupy a position from which their dysfunction can propagate outward to compromise synaptic transmission, plasticity, and ultimately behavior. This review synthesizes current evidence indicating that opioids, psychostimulants, alcohol, cannabinoids, and nicotine, despite engaging distinct primary pharmacological targets, converge on a common downstream phenotype of impaired oxidative phosphorylation, excessive reactive oxygen species production, disrupted mitochondrial fission–fusion dynamics, and defective mitophagy. Building on, and extending, existing cross-substance syntheses of drug-induced mitochondrial dysfunction, we integrate evidence on the signaling architecture, PGC-1α/NRF1/2, sirtuins, AMPK–mTOR, and BDNF–CREB, that couples mitochondrial quality control to synaptic plasticity, and we examine how oxidative, neuroinflammatory, and epigenetic mechanisms, including reciprocal signaling among neurons, astrocytes, and microglia, interact to convert transient drug-induced bioenergetic stress into durable, self-perpetuating dysfunction. Mapping these mechanisms onto the initiation, maintenance, and withdrawal/relapse phases of the addiction cycle reveals a dynamic trajectory in which mitochondria shift from an adaptively taxed to a chronically failing state, with direct implications for craving and relapse vulnerability. Finally, we critically evaluate mitochondria-targeted antioxidants, biogenesis modulators, exercise, metabolic interventions, and emerging biomarker-based strategies as candidate interventions, and we propose an integrated bioenergetic framework in which mitochondrial health functions both as a biological substrate and as a measurable target for understanding and treating substance use disorders. Because the underlying evidence base is drawn largely from preclinical and, in places, non-addiction models, we treat the relationship between mitochondrial dysfunction and addiction, whether causal, consequential, or self-perpetuating, as an open empirical question, and we present the resulting synthesis as a testable, stage-resolved theoretical framework rather than as an established mechanism.
- 1 October 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-26
Open AccessMitochondrial Dysfunction Across the Addiction Cycle: A Stage-Resolved Narrative Review
Addiction is a chronic, relapsing brain disorder defined by compulsive drug use, diminished self-control, and persistent vulnerability to relapse. Although addiction is conventionally framed in terms of synaptic and circuit-level adaptations within the mesolimbic dopamine system, prefrontal cortex, hippocampus, and amygdala, accumulating evidence indicates that these neuroadaptations are themselves substantially dependent on the bioenergetic integrity of the neurons that compose these circuits. Mitochondria, as the principal site of ATP synthesis, calcium buffering, and redox regulation, occupy a position from which their dysfunction can propagate outward to compromise synaptic transmission, plasticity, and ultimately behavior. This review synthesizes current evidence indicating that opioids, psychostimulants, alcohol, cannabinoids, and nicotine, despite engaging distinct primary pharmacological targets, converge on a common downstream phenotype of impaired oxidative phosphorylation, excessive reactive oxygen species production, disrupted mitochondrial fission–fusion dynamics, and defective mitophagy. Building on, and extending, existing cross-substance syntheses of drug-induced mitochondrial dysfunction, we integrate evidence on the signaling architecture, PGC-1α/NRF1/2, sirtuins, AMPK–mTOR, and BDNF–CREB, that couples mitochondrial quality control to synaptic plasticity, and we examine how oxidative, neuroinflammatory, and epigenetic mechanisms, including reciprocal signaling among neurons, astrocytes, and microglia, interact to convert transient drug-induced bioenergetic stress into durable, self-perpetuating dysfunction. Mapping these mechanisms onto the initiation, maintenance, and withdrawal/relapse phases of the addiction cycle reveals a dynamic trajectory in which mitochondria shift from an adaptively taxed to a chronically failing state, with direct implications for craving and relapse vulnerability. Finally, we critically evaluate mitochondria-targeted antioxidants, biogenesis modulators, exercise, metabolic interventions, and emerging biomarker-based strategies as candidate interventions, and we propose an integrated bioenergetic framework in which mitochondrial health functions both as a biological substrate and as a measurable target for understanding and treating substance use disorders. Because the underlying evidence base is drawn largely from preclinical and, in places, non-addiction models, we treat the relationship between mitochondrial dysfunction and addiction, whether causal, consequential, or self-perpetuating, as an open empirical question, and we present the resulting synthesis as a testable, stage-resolved theoretical framework rather than as an established mechanism.
- Open Access
- 13 December 2021
- Published by Knowledge E DMCC in Iranian Journal of Psychiatry
- Vol. 17 (1) , 1-13
Lapse and Relapse Rates in Narcotics Anonymous Versus Methadone Maintenance Treatment: A 12-Month Prospective Study
Objective: The present study aimed to compare lapse and relapse-free survival between patients treated in Narcotics Anonymous (NA) groups and Methadone Maintenance Treatment (MMT) centers and to determine the relationship between social support scale and treatment outcome. Method: This study was a prospective, 12-month cohort study using the random sampling method to select 100 newcomer patients treated by the NA Association as well as 100 patients in MMT centers. The data were collected using a demographic questionnaire and Social Support Appraisals (SSA) scale at the onset of the study along with follow-up phone calls every other week. Results: All participants were male, aged between 18 and 65 with a mean (SD) age of 38.98 (± 10.85) years. Prevalence of relapse in 12 months was 60.5%. The lapses in the MMT group and relapses in the NA group were significantly higher (P < 0.001). The younger patients with lower levels of education are at greater risk of lapse/relapse. The mean score of SSA was significantly higher in the MMT group than the NA group in all subscales, including friends, family, and the others' support (P < 0.001). The mean scores of SSA subscales for the participants without relapse in the NA group was significantly higher in comparison to the MMT group. Conclusion: Detection of factors related to drug abuse relapse/lapse may help addiction therapists to identify drug abuse patients with lapse/relapse and to develop treatment and policy guidelines to prevent relapse in addiction recovery.
- 13 December 2021
- Published by Knowledge E DMCC in Iranian Journal of Psychiatry
- Vol. 17 (1) , 1-13
Open AccessLapse and Relapse Rates in Narcotics Anonymous Versus Methadone Maintenance Treatment: A 12-Month Prospective Study
Objective: The present study aimed to compare lapse and relapse-free survival between patients treated in Narcotics Anonymous (NA) groups and Methadone Maintenance Treatment (MMT) centers and to determine the relationship between social support scale and treatment outcome. Method: This study was a prospective, 12-month cohort study using the random sampling method to select 100 newcomer patients treated by the NA Association as well as 100 patients in MMT centers. The data were collected using a demographic questionnaire and Social Support Appraisals (SSA) scale at the onset of the study along with follow-up phone calls every other week. Results: All participants were male, aged between 18 and 65 with a mean (SD) age of 38.98 (± 10.85) years. Prevalence of relapse in 12 months was 60.5%. The lapses in the MMT group and relapses in the NA group were significantly higher (P < 0.001). The younger patients with lower levels of education are at greater risk of lapse/relapse. The mean score of SSA was significantly higher in the MMT group than the NA group in all subscales, including friends, family, and the others' support (P < 0.001). The mean scores of SSA subscales for the participants without relapse in the NA group was significantly higher in comparison to the MMT group. Conclusion: Detection of factors related to drug abuse relapse/lapse may help addiction therapists to identify drug abuse patients with lapse/relapse and to develop treatment and policy guidelines to prevent relapse in addiction recovery.